1,508
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Diagnostic, prognostic and predictive values of miR-100 and miR-210 in pediatric acute lymphoblastic Leukemia

, , , , &

References

  • Mezei G, Sudan M, Izraeli S, et al. Epidemiology of childhood leukemia in the presence and absence of Down syndrome. Cancer Epidemiol. 2014;38:479–489.
  • Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukemia. Lancet. 2013;381:1943–1955.
  • Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541–1552.
  • Ding LW, Sun QY, Tan KT, et al. Mutational landscape of pediatric acute lymphoblastic leukemia. Cancer Res. 2017;77:390–400.
  • Tasian SK, Hunger SP. Genomic characterization of pediatric acute lymphoblastic leukemia:an opportunity for precision medicine therapeutics. Br J Haematol. 2017;176:867–882.
  • Roberts KG, Mullighan CG. Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nat Rev Clin Oncol. 2015;12:344–357.
  • Liu XL, Liu HQ, Li J, et al. Role of epigenetic in leukemia: from mechanism to therapy. Chem Biol Interact. 2020;317:108963.
  • Valencia-Sanchez MA, Liu J, Hannon GJ, et al. Control of translation and mRNA degradation by miRs and siRNAs. Genes Dev. 2006;20:515–524.
  • de Oliveira JC, Brassesco MS, Scrideli CA, et al. MicroRNA expression and activity in pediatric acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer. 2012;59:599–604.
  • Carvalho de Oliveira J, Molinari Roberto G, Baroni M, et al. Mir dysregulation in childhood hematological cancer. Int J Mol Sci. 2018;19:2688.
  • Li X-J, Luo X-Q, Han B-W, et al. MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways. Br J Cancer. 2013;109:2189–2198.
  • Noman MZ, Buart S, Romero P, et al. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res. 2012;72(18):4629–4641.
  • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
  • Ultimo S, Martelli AM, Zauli G, et al. Roles and clinical implications of microRNAs in acute lymphoblastic leukemia. J Cell Physiol. 2018 Aug;233(8):5642–5654.
  • Luan C, Yang Z, Chen B. The functional role of microRNA in acute lymphoblastic leukemia: relevance for diagnosis, differential diagnosis, prognosis, and therapy. Onco Targets Ther. 2015;8:2903.
  • Daniel AA, Attilio O, Robert H, et al. Revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
  • Campana D. Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol. 2009;46(1):100–106.
  • Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods. 2001 Dec;25(4):402–408.
  • Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26):2730–2741.
  • de Oliveira JC, Scrideli CA, Brassesco MS, et al. Differential miRNA expression in childhood acute lymphoblastic leukemia and association with clinical and biological features. Leuk Res. 2012 Mar;36(3):293–298.
  • Schotte D, De Menezes RX, Moqadam FA, et al. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica. 2011 May;96(5):703–711.
  • Zhang H, Luo XQ, Zhang P, et al. MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PloS One. 2009;4(11):e7826.
  • Xue Y, Yang X, Hu S, et al. A genetic variant in miR-100 is a protective factor of childhood acute lymphoblastic leukemia. Cancer Med. 2019 May;8(5):2553–2560.
  • Umerez M, Garcia-Obregon S, Martin-Guerrero I, et al. Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia. Pharmacogenomics. 2018 Mar;19(4):361–373.
  • Mei Y, Li Z, Zhang Y, et al. Low miR-210 and CASP8AP2 expression is associated with a poor outcome in pediatric acute lymphoblastic leukemia. Oncol Lett. 2017;14(6):8072–8077.
  • Rashed WM, Hamza MM, Matboli M, et al. MicroRNA as a prognostic biomarker for survival in childhood acute lymphoblastic leukemia: a systematic review. Cancer Metastasis Rev. 2019 Dec;38(4):771–782.